A record of what Jefferies Analysis said publicly, with the source. Not advice.
Pending — not yet graded
“Jefferies recommends buying Torrent Pharmaceuticals, projecting a potential upside of 22-28% over the next 12 months. Despite expected challenges, the firm sees potential growth, with a target price ranging from ₹1,400 to ₹3,970.”
Jefferies Analysis’s track record (trackable calls only): 153 graded calls · 95% CI 37–53%
Torrent PharmaceuticalsBullishCalled 27 Jan 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.